Ardelyx (41X) Stock Price & Analysis
41X Stock Chart & Stats
- Day’s Range
- EUR 2.74 - EUR 2.74
- 52-Week Range
- EUR 2.66 - EUR 6.75
- Previous Close
- EUR 2.76
- Volume
- 0
- Average Volume (3M)
- 83
- Market Cap
- EUR 676.06M
- Enterprise Value
- EUR 1.24B
- Total Cash (Recent Filing)
- EUR 281.83M
- Total Debt (Recent Filing)
- EUR 256.19M
- Price to Earnings (P/E)
- ―
- Beta
- 0.48
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross Margins
Ardelyx has built substantial commercial scale, with revenue rising sharply and gross margins remaining very high. The narrowing net loss indicates operating leverage is emerging, so continued product adoption could improve earnings power and support a transition toward profitability over the next several quarters.
Strong Adoption Of Both Commercial Products
Double-digit growth across both marketed products reduces reliance on a single growth engine and demonstrates continued physician and patient adoption. Expanded sales and reimbursement teams, plus improved fulfillment through the IPN, can reinforce prescription conversion, persistence, and commercial execution.
Pipeline And Intellectual-property Support
Advancing ACCEL in chronic idiopathic constipation gives Ardelyx an opportunity to extend tenapanor into an additional indication and leverage existing commercial capabilities. A long patent runway could preserve exclusivity and support durable product economics if development and regulatory objectives are achieved.
Bears Say
Persistent Negative Cash Generation
The company still consumes cash rather than funding operations internally, leaving profitability and continued revenue growth essential to financial stability. If cash flow does not turn positive, Ardelyx may need additional debt or equity financing, which could reduce flexibility for pipeline investment and commercial expansion.
Rising Leverage And Limited Financial Flexibility
Debt has increased materially as Ardelyx has scaled, and borrowings now exceed equity by a meaningful margin. Until operating profits and cash generation improve, higher leverage can increase financing obligations, constrain capital allocation, and make the business less resilient if commercial execution or reimbursement conditions weaken.
Payer Barriers Reduce Near-term IBSRELA Visibility
More restrictive payer controls create friction between prescriptions and realized sales, potentially extending the time required to acquire new patients. This pressure has already reduced guidance, and sustained access hurdles could raise commercialization costs, delay scale benefits, and make the path to profitability less predictable.
Ardelyx News
Ardelyx (ARDX) Investors File Securities Lawsuit After 18% Stock Drop Over Alleged Drug Revenue and Payer Disclosures
Ardelyx, Inc. ($ARDX) is facing a federal securities lawsuit after its shares fell sharply when the company cut its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue
41X FAQ
What was Ardelyx’s price range in the past 12 months?
What is Ardelyx’s market cap?
When is Ardelyx’s upcoming earnings report date?
How were Ardelyx’s earnings last quarter?
Is Ardelyx overvalued?
Does Ardelyx pay dividends?
What is Ardelyx’s EPS estimate?
How many shares outstanding does Ardelyx have?
What happened to Ardelyx’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ardelyx?
What is the TipRanks Smart Score and how is it calculated?
Ardelyx Stock Smart Score
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael G. Raab
- Employees
- 489
- Website
- www.ardelyx.com
- Address
- 400 Fifth Avenue, Waltham, MA, 02451, US
Ardelyx (41X) Earnings & Revenues
41X Company Deck
41X Earnings Call
Earnings Call SentimentPositive
The call presents a predominantly constructive commercial and financial picture — record quarterly revenue, double-digit year-over-year growth for both marketed products, improving losses and a pathway to profitability in 2027 — but is tempered by material payer-access headwinds that slowed new patient starts for IBSRELA, a lowered near-term guidance for IBSRELA, increased operating costs to address access challenges, and pulled longer-range XPHOZAH guidance pending regulatory/market clarity. Management has taken proactive remediation steps (IPN, enlarged FRM team, expanded sales force), retains confidence in long-term potential (including $1 billion IBSRELA ambition and tenapanor IP), and maintains solid liquidity, resulting in a net-positive but cautious outlook.
View all DE:41X earnings summaries41X Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 12 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 3 | 0 | 9 |
